ASCO GU 2026: Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery
A new study led by UCLA Health Jonsson Comprehensive Cancer Centre investigators suggests that adding hormone therapy…
Browsing: ASCO
ASCO GI 2026: Key gastrointestinal cancer trials shaping practice across CRC, upper GI and hepatobiliary disease
New data presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI) highlight continued momentum…
ASCO GI 2026: Zanidatamab and chemotherapy can slow cancer growth, extend survival in some people with gastroesophageal adenocarcinoma
Results from a new phase 3 study found that for people with human epidermal growth…
ASCO 2025 Special Part 2! S3E5 The Oncology Journal Club
Welcome to Part 2 of the 2025 ASCO ASM Special of The Oncology Journal Club! Our Host Craig Underhill is joined by Dr Kate Clarke and Professor Christopher Jackson to unpack practice changing presentations from Chicago.
ASCO 2025: Vepdegestrant could extend progression-free survival for some people with ESR1-mutated advanced breast cancer
Results from VERITAC-2, the first global phase 3 clinical trial of a PROTAC, a targeted…
ASCO 2025: Sacituzumab govitecan helps some patients with PD-L1-positive triple-negative breast cancer live longer without cancer progression
Results from an international phase 3 clinical trial show that treatment with sacituzumab govitecan and…
ASCO 2025: Molecular assay may help identify people with NSCLC who could benefit from adjuvant chemotherapy
Results from an international clinical trial show that a 14-gene molecular assay can help identify…
ASCO 2025: Post-hoc analysis demonstrates patient characteristics associated with long-term overall survival with irinotecan liposome injection in metastatic pancreatic adenocarcinoma
Late-breaking data from the Phase III NAPOLI 3 study were presented today at the 2025…
ASCO 2025: Pembrolizumab gives head and neck cancer patients extra years disease-free
An immunotherapy helps patients live years longer without their cancer getting worse or coming back,…
ASCO 2025: Adding nivolumab to chemoradiotherapy after surgery can decrease chance of recurrence in head and neck cancer
Results from the international phase 3 NIVOPOSTOP clinical trial found that adding nivolumab to chemoradiotherapy…